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Case Report
Abstract
Treatment of urachal adenocarcinoma (UA) of the urinary bladder has typically been with radical cystectomy (RC) but more
conservative approaches are gaining popularity. Here we present the case of a female patient with metastatic primary bladder
UA who was treated with robotic partial cystectomy (RPC) and adjuvant chemotherapy; she is alive with no evidence of disease
recurrence or metastatic disease at 5 years. This case provides some of the longest follow-up after RPC to date thereby demon-
strating that RPC is a safe and oncologically viable treatment for selected patients even several years after definitive treatment.
Patients undergoing RPC benefit from the reduced morbidity associated with this less radical treatment whilst enjoying simi-
larly successful oncological outcomes to RC.
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Introduction
Urachal adenocarcinoma (UA) of the urinary bladder is a
rare and aggressive tumour that occurs at the dome or ante-
rior wall of the bladder.1 It is typically associated with an
extremely poor prognosis with many patients found to have
distant metastases at the time of diagnosis.2The gold standard
of treatment for muscle invasive bladder cancer is radical
cystectomy 3, 4 but the alternative of partial cystectomy (PC)
has gained popularity and has been shown to provide com-
parable 5-year survival rates to patients treated with radical
cystectomy.1, 5
In 2006 Milhoua’s team published the successful outcome of
a patient with primary malignant UA who underwent a lap-
aroscopic extended PC and en bloc removal of the urachus
and umbilicus; this patient remained disease-free at 18
months.5 In 2010 Allaparthi’s team published the successful
short-term outcome of a patient with UA who underwent
robotic PC (RPC).6 Here we present the case of a patient
with metastatic UA who underwent robotic PC who is alive
with no evidence of disease recurrence or metastatic disease
at 5 years.
Case presentation
A 49-year-old lady was diagnosed with a large urachal ade-
nocarcinoma with metastatic nodal disease (T4bN3) in 2010,
having been investigated by gynaecology for ‘vaginal bleed-
ing’ for 6 months (Figures 1 and 2).
FIG. 1: Initial MRI scans showing this patient’s large urachal adeno-
carcinoma.
FIG. 2: Initial MRI scans showing this patient’s large urachal adeno-
carcinoma.
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The tumour was invading the omentum and she underwent
robotic PC, with en bloc removal of a patch of omentum in
June 2008. 24 pelvic nodes were removed, with 3 nodes on
the left found to be positive. A left superficial groin dissec-
tion revealed 1 positive node, which measured over 5 cm.
Estimated blood loss (EBL) was 150 ml, and she was dis-
charged after three nights in hospital. She subsequently had
four cycles of adjuvant oxaliplatin and capecitabine and she
remains well with no recurrence or evidence of metastatic
disease. Her pre- and post-treatment PET scans are shown
below (Figures 3 and 4); these show the remarkable and
complete response to treatment.
FIG. 3: Initial PET scan in March 2010 (pre-treatment).
FIG. 4: PET scan 42 months post-surgery and chemotherapy show-
ing complete response to treatment.
Discussion
This case shows that the more conservative treatment option
of robotic partial cystectomy can provide successful onco-
logical results even for patients with advanced metastatic
disease. Our case demonstrates that these successful onco-
logical results are also seen several years after treatment,
with previously published cases only reporting data of fol-
low-up of several months. That RPC can provide comparable
oncological results to radical cystectomy is an important
advance in urological, and robotic urological, practice for
several reasons. First, by undergoing RPC patients avoid the
long-term consequences of requiring a urinary diversion
system, such as psychological and cosmetic issues, as well as
the risk of hyperchloraemic metabolic acidosis. The early
post-operative complications associated with RC, such as
dehydration, are also avoided; these have been quoted as
occurring in up to 28% of patients undergoing RC.7 Second,
RPC provides a curative treatment option for patients with
too poor a functional status to undergo radical cystectomy.3
Third, as is the case for robotic surgery in general, robotic PC
is associated with a faster postoperative recovery, less post-
operative pain and improved post-operative cosmetic ap-
pearance.8, 9
This case also demonstrates a good response of UA to chem-
otherapy, contrary to what has been previously shown.1, 10
Further research is needed to establish the role of adjuvant
chemotherapy in treating UA.
One of the main concerns regarding the use of PC has been
of recurrence within the bladder, distal ureter and the pros-
tate in men, with two large studies recording local recur-
rence rates of up to 35%.6 However, the largest, and more
recent, study of UA to date reported more modest recurrence
rates; 15% of patients with non-metastatic UA developed
local recurrence, and this was usually after partial cystecto-
my.1 However, there was no difference in survival rates be-
tween patients who underwent partial cystectomy versus
radical cystectomy.
UA is a rare pathology with the details of around only 400
cases previously published. Only a few of these patients have
been treated with robotic partial cystectomy, and there is
currently only short-term follow-up of these patients, albeit
good responses to treatment in the short-term. Here we pro-
vide data to show that patients with aggressive UA are un-
dergoing less invasive surgery and remaining disease-free
without recurrence several years down the line.
Conclusion
There is an increasing body of evidence in the literature to
suggest that robotic partial cystectomy is an oncologically
safe and feasible curative treatment option for patients with
urachal adenocarcinoma, and that its results are comparable
with radical cystectomy. This case adds some further evi-
dence to the literature but the success of RPC for this rare
malignancy needs to be verified with further studies and
more long-term follow-up.
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